Table 3 Ongoing clinical trials of IDH1 inhibitors in adult AML
From: Isocitrate dehydrogenase inhibitors in acute myeloid leukemia
NCT Number | Phase | disease | Interventions | Status |
|---|---|---|---|---|
NCT04013880 | Phase 1/2 | R/R AML | FT-2102 plus ASTX727 | Not yet recruiting |
NCT02719574 | Phase 1/2 | AML | FT-2102 as single agent; FT-2102 plus azacitidine/ cytarabine; | Recruiting |
NCT03471260 | Phase 1/2 | R/R AML | Ivosidenib plus Venetoclax with or without azacitidine | Recruiting |
NCT02074839 | Phase 1 | R/R AML; Untreated AML; | ivosidenib | Active, not recruiting |
NCT02677922 | Phase 1/2 | Newly Diagnosed AML | Ivosidenib plus Azacitidine | Active, not recruiting |
NCT03173248 | Phase 3 | Untreated AML | Ivosidenib plus azacitidine vs placebo plus azacitidine | Recruiting |
NCT02632708 | Phase 1 | Newly Diagnosed AML | Ivosidenib plus standard chemotherapy | Active, not recruiting |
NCT03839771 | Phase 3 | Newly Diagnosed AML | Ivosidenib plus standard chemotherapy | Recruiting |
NCT03013998 | Phase 1/2 | Previously Untreated AML | ivosidenib | Recruiting |